Hepatotoxicity In Anti-Tuberculosis Therapy: An Observational Study

Objectives: To determine the hepatotoxicity in patients receiving therapy against tuberculosis, determine the frequency & at which age chances of hepatotoxicity are more .And how to reduce these side effects.Methodology: A randomized study was conducted on 100 patients in Tuberculosis Hospital, district headquarter hospital Jhang during July and August-2015. A questionnaire was designed to diagnose hepatotoxicity in patients undergoing tuberculosis therapy. As the important parameter for hepatotoxicity measurement is liver function test, so the major tests of liver function test were performed like, alanine aminotransferase, aspartate aminotransferase and bilirubin.Results: Ratio of patients showing hepatotoxicity both males and females indicates that females are more hepatotoxic as compared to male. In the age range of 31-60 hepatotoxicity cases were more. The combination of two drugs isoniazid & rifampicin shows more hepatotoxicity.Conclusion: It was concluded that the combination of isoniazd id & rifampicin showed more hepatotoxicity than combination with ofloxacin & pyrazinamide. Moreover, antituberculosis therapy having ofloxacin in the absence of rifampicin was more efficacious.